The CelioFlex UHD probes are designed to provide visualization of body cavities, organs and canals during endoscopic, laparoscopic and robotic-assisted procedures, the Paris-based company said.
“This new FDA clearance is an important milestone for the company on its Cellvizio product roadmap and market expansion strategy. We see the ability to instantaneously visualize and characterize tissue at the cellular level as a natural extension to robotic-assisted procedures and enabling data-driven surgery, which will in-part rely on advanced imaging and machine learning algorithms to provide reliable, real-time tissue information to surgeons,” founder & CEO Sacha Loiseau said in a press release.
Last month, Mauna Kea touted the results from a recently published study of its Cellvizio system which supported the use of the device in diagnosing pancreatic cysts.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!